Cargando…
Perspectives of CB1 Antagonist in Treatment of Obesity: Experience of RIO-Asia
Rimonabant, a selective cannabinoid-1 (CB1) receptor antagonist, has been shown to reduce weight and enhance improvements in cardiometabolic risk parameters in Western populations. This study assessed these effects of rimonabant in Asian population. A total of 643 patients (BMI 25 kg/m(2) or greater...
Autores principales: | Pan, Changyu, Yoo, Hyung Joon, Ho, Low-Tone |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3021887/ https://www.ncbi.nlm.nih.gov/pubmed/21253513 http://dx.doi.org/10.1155/2011/957268 |
Ejemplares similares
-
The rise and fall of CB(1) receptor antagonists: possible future perspectives
por: Bagdy, György
Publicado: (2011) -
Variations in Practice among Asia–Pacific Surgeons and Recommendations for Managing Cervical Myelopathy: The First Asia–Pacific Spine Society Collaborative Study
por: Cheung, Jason Pui Yin, et al.
Publicado: (2019) -
Cannabinoid(1) (CB-1) receptor antagonists: a molecular approach to treating acute cannabinoid overdose
por: Skolnick, Phil, et al.
Publicado: (2019) -
The CB-ELSA experiment
por: Ehmanns, A
Publicado: (2000) -
Role of Socioeconomic Indicators on Development of Obesity from a Life Course Perspective
por: Salonen, Minna K., et al.
Publicado: (2009)